Publications by authors named "James Monn"

Claim this Profile
M
mGlu3 Metabotropic Glutamate Receptors as a Target for the Treatment of Absence Epilepsy: Preclinical and Human Genetics Data.
Roberta Celli, Pasquale Striano, Rita Citraro, Luisa Di Menna, Milena Cannella, James A Monn

Curr Neuropharmacol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabotropic Glutamate Receptors Modulate Exocytotic Tau Release and Propagation.
Francesca Mazzo, Ioana Butnaru, Olivera Grubisha, Elena Ficulle, Helen Sanger, James Monn

J Pharmacol Exp Ther· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Behavioural and biochemical responses to methamphetamine are differentially regulated by mGlu2 and mGlu3 metabotropic glutamate receptors in male mice.
Carla L Busceti, Roxana P Ginerete, Luisa Di Menna, Giovanna D'Errico, Francesca Cisani, James A Monn

Neuropharmacology· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural Basis for ( S)-3,4-Dicarboxyphenylglycine (DCPG) As a Potent and Subtype Selective Agonist of the mGlu Receptor.
Qi Chen, Joseph D Ho, Sheela Ashok, Michelle C Vargas, Jing Wang, James A Monn

J Med Chem· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Pharmacological Characterization of C4-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu Receptor Agonist.
James A Monn, Steven S Henry, Steven M Massey, David K Clawson, Qi Chen

J Med Chem· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabotropic Glutamate Receptors Play a Key Role in Modulating Head Twitches Induced by a Serotonergic Hallucinogen in Mice.
Mark J Benvenga, Stephen F Chaney, Melvyn Baez, Thomas C Britton, William J Hornback, James A Monn

Front Pharmacol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determination of L-AP4-bound human mGlu8 receptor amino terminal domain structure and the molecular basis for L-AP4's group III mGlu receptor functional potency and selectivity.
Jeffery M Schkeryantz, Qi Chen, Joseph D Ho, Shane Atwell, Aiping Zhang, James A Monn

Bioorg Med Chem Lett· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Broad spectrum efficacy with LY2969822, an oral prodrug of metabotropic glutamate 2/3 receptor agonist LY2934747, in rodent pain models.
Michael P Johnson, Mark A Muhlhauser, Eric S Nisenbaum, Rosa M A Simmons, Beth M Forster, James A Monn

Br J Pharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational Pharmacology of the Metabotropic Glutamate 2 Receptor-Preferring Agonist LY2812223 in the Animal and Human Brain.
Christian C Felder, Douglas A Schober, Yuan Tu, Anne Quets, Hongling Xiao, James A Monn

J Pharmacol Exp Ther· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu receptor antagonist.
Jeffrey M Witkin, Paul L Ornstein, Charles H Mitch, Renhua Li, Stephon C Smith, James A Monn

Neuropharmacology· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.
Mark D Chappell, Renhua Li, Stephon C Smith, Bruce A Dressman, Eric G Tromiczak, James A Monn

J Med Chem· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.
James A Monn, Lourdes Prieto, Lorena Taboada, Junliang Hao, Matthew R Reinhard

J Med Chem· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain structures.
James A Monn, Lourdes Prieto, Lorena Taboada, Concepcion Pedregal, Junliang Hao

J Med Chem· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740.
Rosamaria Orlando, Marina Borro, Marta Motolese, Gemma Molinaro, Sergio Scaccianoce, James A Monn

Neuropharmacology· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonists.
James A Monn, Matthew J Valli, Steven M Massey, Junliang Hao, Matthew R Reinhard

J Med Chem· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography.
Rebecca A Wright, Bryan G Johnson, Ce Zhang, Craig Salhoff, Ann E Kingston, James A Monn

Neuropharmacology· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist.
Lydia Hanna, Laura Ceolin, Sarah Lucas, James Monn, Bryan Johnson

Neuropharmacology· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR.
Helen Sanger, Lydia Hanna, Ellen M Colvin, Olivera Grubisha, Daniel Ursu, James A Monn

Neuropharmacology· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulator.
Junliang Hao, Veronique Dehlinger, Adam M Fivush, Helene C E Rudyk, Thomas C Britton, James A Monn

Bioorg Med Chem Lett· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved synthesis of C4α- and C4β-methyl analogues of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate.
Steven S Henry, Molly D Brady, Dana L T Laird, J Craig Ruble, David L Varie, James A Monn

Org Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
Matthew J Fell, David L McKinzie, James A Monn, Kjell A Svensson

Neuropharmacology· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study of novel selective mGlu2 agonist in the temporo-ammonic input to CA1 neurons reveals reduced mGlu2 receptor expression in a Wistar substrain with an anxiety-like phenotype.
Laura Ceolin, Sriharsha Kantamneni, Gareth R I Barker, Lydia Hanna, Laura Murray, James A Monn

J Neurosci· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).
Matthew J Fell, Kenneth W Perry, Julie F Falcone, Bryan G Johnson, Vanessa N Barth, James A Monn

J Pharmacol Exp Ther· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, James A Monn

Nat Med· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Linda M Rorick-Kehn, Bryan G Johnson, Karen M Knitowski, Craig R Salhoff, Jeffrey M Witkin, James A Monn

Psychopharmacology (Berl)· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis